VEGFA and retinopathy of prematurity: Ranibizumab, a classical therapeutic agent for ROP, is a monoclonal antibody fragment against VEGFA, and clinical studies have shown that its treatment success rate for ROP is equivalent to that of laser therapy [28, 29].